Mammary carcinoma: toward a realistic mouse model of incurable cancers

Maria Pérez-Lanzón; Maria Chiara Maiuri; Carlos Lopez-Otin; Guido Kroemer

doi:10.1080/2162402X.2023.2240613

Mammary carcinoma: toward a realistic mouse model of incurable cancers

Oncoimmunology. 2023 Aug 3;12(1):2240613. doi: 10.1080/2162402X.2023.2240613. eCollection 2023.

Authors

Maria Pérez-Lanzón^{1

2}, Maria Chiara Maiuri^{1

2

3}, Carlos Lopez-Otin⁴, Guido Kroemer^{1

2

5}

Affiliations

¹ Centre de Recherche des Cordeliers, Équipe Labellisée Par la Ligue Contre le Cancer, Inserm U1138, Université Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.
² Metabolomics and Cell Biology Platforms, UMS AMICCa, Gustave Roussy, Villejuif, France.
³ Department of Molecular Medicine and Medical Biotechnologies, University of Napoli Federico II, Napoli, Italy.
⁴ Departamento de Bioquimica Y Biologia Molecular, Instituto Universitario de Oncologia (IUOPA), Universidad de Oviedo, Oviedo, Spain.
⁵ Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, France-HP, Paris, France.

Abstract

As long as breast cancer (BC) stays under immunosurveillance, it can be controlled by treatments eliciting anticancer immune responses. However, once BC escapes immunosurveillance, it becomes therapeutically uncontrollable. A paper in the Journal for ImmunoTherapy of Cancer describes a new hormone receptor-positive BC cell line generating incurable tumors in C57BL/6 mice.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Carcinoma*
Immunotherapy*
Mice
Mice, Inbred C57BL

Grants and funding

GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council Advanced Investigator Award (ERC-2021-ADG, ICD-Cancer, Grant No. 101052444), European Union Horizon 2020 Projects Oncobiome, Prevalung (grant No. 101095604) and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001.